Today: 19 January 2026
Subscribe
Browse Category

Healthcare Innovation News 4 November 2025 - 13 January 2026

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

New York, Jan 13, 2026, 11:51 EST — Regular session Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration’s request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo…
13 January 2026
···
Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates

Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates

New York, Jan 7, 2026, 14:25 EST — Regular session Johnson & Johnson shares rose 0.9% to $206.62 on Wednesday, after the healthcare company said it filed its OTTAVA robotic surgical system with U.S. regulators. The stock traded between $204.62 and $208.25. The filing puts fresh attention on J&J’s MedTech push, a part of the business investors want to see…
7 January 2026
····
4DMedical shares jump on UC San Diego Health CT:VQ rollout as market eyes next catalyst

4DMedical shares jump on UC San Diego Health CT:VQ rollout as market eyes next catalyst

Sydney, Jan 7, 2026, 17:44 AEDT — Market closed Shares of 4DMedical Ltd (ASX:4DX) climbed 11.9% to close at A$4.69 on Wednesday after the firm said UC San Diego Health had adopted its CT:VQ lung imaging software for clinical use. About 12.8 million shares traded, MarketScreener data showed. MarketScreener The contract adds a fourth U.S. academic medical centre — a…
7 January 2026
···
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading…
30 December 2025
····
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical, Inc. (NYSE American: PMI) just staged one of the most dramatic moves on Wall Street, with its stock surging more than 80% on December 4, 2025, after the company released new data on its next‑generation artificial heart. Investors are now asking a simple question: is this the start of a longer rerating, or just another spike in a…
5 December 2025
····
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday swings between roughly $12.5 and $18.2 and volume near 26 million shares – over 20× its recent average. MarketBeat Behind…
4 December 2025
····
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

On December 2, 2025, Polyrizon Ltd. (NASDAQ: PLRZ) went from obscure micro-cap to center stage as its stock exploded more than 130% in a single session after the company announced a key manufacturing milestone for its flagship nasal spray platform. MarketScreener The move capped one of the wildest trading days the stock has seen since its 2024 IPO: shares closed…
2 December 2025
···
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock. The Motley Fool Below is a detailed look at where AbbVie’s stock stands today, what has changed since late November, and…
1 December 2025
····
Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Published: November 18, 2025 Medtronic plc (NYSE: MDT) is back in the spotlight today after reporting stronger‑than‑expected results for the second quarter of fiscal 2026 and raising its full‑year outlook. The medical technology giant delivered solid revenue and earnings growth, highlighted powerful momentum in its cardiac ablation franchise, and signaled confidence in accelerating growth in the second half of the…
18 November 2025
···
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters Key points at a glance Deal terms: a rich premium for a single late‑stage asset…
14 November 2025
···
Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health, Inc. (NYSE: OSCR) announced new individual-market plans for South Florida ahead of the 2026 Open Enrollment window and spotlighted HelloMeno, a menopause-focused offering it and partner Elektra Health describe as the first plan of its kind in the individual market. The rollout lands as Washington headlines around ACA premium tax credits pressure managed-care shares broadly; investors are watching…
10 November 2025
···
Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Company Overview: Telehealth for High-Acuity Care VSee Health, Inc. is a Silicon Valley-founded telehealth technology and services provider specializing in high-acuity virtual care. Founded in 2008 by Dr. Milton Chen, VSee built a secure video telemedicine platform so robust it was even utilized by NASA for astronaut healthcare Businesswire. Today, after merging with iDoc Telehealth via a SPAC deal in…
4 November 2025
·
1 2

Stock Market Today

  • Is It Too Late To Buy Repligen Corporation (NASDAQ:RGEN)?
    January 19, 2026, 6:40 AM EST. Repligen Corporation (NASDAQ:RGEN) has seen a 10% surge in share price recently but remains below its intrinsic value of $233.58, suggesting a potential buying opportunity. The biotech firm's earnings are forecasted to double in the coming years, signaling strong growth prospects. However, its high beta indicates price volatility that may lead to significant swings amid market downturns. Investors should weigh the optimistic outlook against Repligen's financial health and noted warning signs before committing. Current undervaluation may appeal to shareholders and new investors seeking growth, but caution is warranted given market risks and company-specific factors.
Go toTop